Company intelligence / Profile preview

Parthenon Therapeutics

Cambridge, Massachusetts, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Currently conducting a Phase 1 clinical trial for lead candidate PRTH-101, a DDR1 inhibitor that targets collagen barriers in immune excluded tumors. The company plans to start a pivotal Phase 2 trial of PRTH-101 in the second half of 2025.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

PRTH-101

Phase 1

Indications: Solid tumors

Partnerships

UTHealth HoustonGeorge Washington University

Beyond the preview

Go deeper on Parthenon Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Parthenon Therapeutics.

Explore the full profile